Findings

What do systematic reviews say?

5 questions · 5 findings · 5 reviews · Oral medicine and oral cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 60%GRADE not reported 2 · 40%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Systemic oral acyclovir vs Placebo or no treatment · Direct costs (medication, hospital bed days)
  Acyclovir for treating primary herpetic gingivostomatitis 2008 · Cochrane All outcomes
  No data available in either included study.
  Studies not reported
  No studies found
Direct match · question page
- EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) · Direct and indirect costs to participants and health services
  Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
  24 to 70 months
  No included studies addressed direct and indirect costs to participants and health services (review-wide gap).
  0 studies
  No studies found
Direct match · question page
- Amifostine vs No treatment/placebo · Cost (mean per-patient supportive care costs)
  Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  End of RT
  Mean per-patient supportive care costs lower with amifostine (USD 4401) than control (USD 5873); P = 0.02 (Buntzel 1998 / Bennett 2001)
  1 study · 28 participants
  GRADE not reported
Direct match · question page
- Visual screening (oral visual inspection) by trained health workers vs No screening · Costs
  Screening programmes for the early detection and prevention of oral cancer 2013 · Cochrane All outcomes
  9 years (three cycles)
  The costs associated with the screening programme were reported after three cycles (nine years) (Subramanian 2009) (Additional Table 8). The benefit produced by a screen was 269.31 life-years saved per 100,000 for all…
  1 study
  GRADE not reported
Direct match · question page
- Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment · Direct costs
  Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes
  The trials did not measure costs.
  0 studies
  No studies found

Visual screening (oral visual inspection) by trained health workers vs No screening

Costs · Apparently healthy adults aged 35 years or older (general population), living in 13 clusters in rural areas of Trivandrum city, Kerala,…

1 finding from 1 review

Screening programmes for the early detection and prevention of oral cancer 2013 · Cochrane All outcomes
9 years (three cycles)
The costs associated with the screening programme were reported after three cycles (nine years) (Subramanian 2009) (Additional Table 8). The benefit produced by a screen was 269.31 life-years saved per 100,000 for all…
1 study
GRADE not reported

Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment

Economic: direct costs · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes
The trials did not measure costs.
0 studies
No studies found

Systemic oral acyclovir vs placebo or no treatment

Direct costs (medication, hospital bed days) · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)

The review found no eligible studies for this question.

1 finding from 1 review

Acyclovir for treating primary herpetic gingivostomatitis 2008 · Cochrane All outcomes
No data available in either included study.
Studies not reported
No studies found

Amifostine vs no treatment/placebo

Cost (mean per-patient supportive care costs) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
Mean per-patient supportive care costs lower with amifostine (USD 4401) than control (USD 5873); P = 0.02 (Buntzel 1998 / Bennett 2001)
1 study · 28 participants
GRADE not reported

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months
No included studies addressed direct and indirect costs to participants and health services (review-wide gap).
0 studies
No studies found